137417-08-4

Basic information

• Product Name: (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride
• CAS NO: 137417-08-4
• Molecular Formula: C17H17NO2
• Molecular Weight: 267.32238
• Mol File: 137417-08-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride(137417-08-4)
• EPA Substance Registry System: (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride(137417-08-4)

Safety Data

• Hazardous Substances Data: 137417-08-4(Hazardous Substances Data)

Usage

Description

(±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride is a benzo phenanthridine alkaloid compound that exists in hydrochloride salt form. It has been identified for its potential biological activities, such as antiviral, anti-inflammatory, and anticancer properties, as well as its potential use in treating neurological disorders and as a research tool in neuroscience.

Uses

Used in Pharmaceutical Industry:
(±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride is used as a pharmaceutical agent for its antiviral, anti-inflammatory, and anticancer properties. It is being studied for its potential to treat various diseases and conditions, including cancer and neurological disorders.
Used in Neuroscience Research:
In the field of neuroscience, (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride is used as a research tool to explore its potential in treating neurological disorders. Its diverse pharmacological activities make it a valuable compound for understanding the underlying mechanisms of these conditions and developing new therapeutic approaches.

Upstream product

• 126295-91-8 dihydrexidine 
• 174691-84-0 dihydrexidine 
• 406174-96-7 N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-methyl-benzenesulfonamide 
• 1315338-46-5 (1R,2R)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-nitro-benzenesulfonamide 
• 1315338-50-1 (6aR,12bS)-10,11-dimethoxy-6-(4-nitrobenzenesulfonyl)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine 
• 1315338-44-3 (1R,2R)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-4-nitro-benzenesulfonamide 
• 85185-33-7 1,2-dimethoxy-4-(4-phenyl-but-3-enyl)benzene 
• 406499-03-4 (6aR,12bS)-(+)-10,11-dimethoxy-5,6,6a,7,8,12b-hexahydrobenzophenanthridine 
• 1345820-59-8 [(R)-1-[(R)-(tert-butyldimethylsilanyloxy)(phenyl)methyl]-3-(3,4-dimethoxyphenyl)propyl]carbamic acid tert-butyl ester 
• 1345820-58-7 [(R)-1-[(R)-(tert-butyldimethylsilanyloxy)phenylmethyl]-3-(3,4-dimethoxyphenyl)allyl]carbamic acid tert-butyl ester 
• 1345820-54-3 [(R)-3-(3,4-dimethoxyphenyl)-1-(R)-(hydroxy(phenyl)methyl)propyl]carbamic acid tert-butyl ester 
• 406174-91-2 (1R,2R)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylamine 
• 123039-93-0 (6a,12b)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine 

Relevant articles and documents

Asymmetric synthesis of a dopamine D1 agonist, dihydrexidine from d-serine

A scalable asymmetric synthesis of trans-2-amino-6,7-dimethoxy-1- phenyltetralin 2 and its N-nosyl derivative 12 have been achieved from Garner aldehyde derived from easily available d-serine using a stereoselective PhMgBr addition, Wittig reaction and TF

A novel and efficient synthesis of dihydrexidine

An efficient synthesis of the dopamine D1 selective full agonist dihydrexidine has been achieved in high yields and requiring no chromatographic separations via a facilitated intramolecular Henry cyclization of a (nitropropyl)benzophenone and subsequent diastereomerically selective reduction of the resulting tricyclic ni- troalkene. Georg Thieme Verlag Stuttgart.

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.